Psoriatic Arthritis
Citrate-free Taltz now available
A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier this year, Eli Lilly and Company announced in a press release.
FDA approves ustekinumab for pediatric psoriatic arthritis
The FDA has approved ustekinumab for the treatment of children aged 6 years and older with active psoriatic arthritis, according to a Janssen press release.
Denial of methotrexate prescriptions post-Roe yields ‘condemnation’
The June 24 Supreme Court decision to overturn Roe vs. Wade continues to reverberate across all of health care, including rheumatology, dermatology and cancer treatment — and in this instance all three at once.
TNF inhibitor tapering non-inferior to non-tapering for LDA maintenance in PsA, axial SpA
A treat-to-target strategy in which TNF inhibitors are tapered is non-inferior to a regimen without tapering for maintaining low disease activity in patients with psoriatic arthritis or axial spondyloarthritis, according to data.
‘One of the few strategy trials in PsA’: CONTROL sheds light on escalation, biologic use
Although there are plenty of drugs to treat psoriatic arthritis, and plenty of studies about those drugs individually, there are fewer trials examining strategies to treat patients who fail to respond to methotrexate in the first line.
Secukinumab 300 mg viable first-line biologic in patients with psoriatic arthritis
Secukinumab 300 mg is a safe and effective first-line biologic for patients with psoriatic arthritis, according to data from a biologic-naïve population based in the United States.
Vitamin D, fish oil ‘unlikely’ to impact RMD progression
Consuming specific dietary components such as vitamin D or omega-3 is “unlikely to influence the progression” of rheumatic and musculoskeletal diseases, according to a report of systemic reviews published in RMD Open.
AI tool may reduce diagnosis time in psoriatic arthritis
A new artificial intelligence tool may improve diagnosis speed in patients with psoriatic arthritis, according to a press release summarizing data from the European Academy of Dermatology and Venereology’s Spring Symposium 2022.
Patients with IMIDs respond well to third COVID-19 vaccine dose
Most patients with immune-mediated inflammatory diseases who had weakened responses to a standard vaccine series for COVID-19 mounted a serological response to a third dose, according to data published in Arthritis and Rheumatology.
Swollen joints a better indicator of synovitis than tender joints in psoriatic arthritis
In patients with early psoriatic arthritis who are naïve to disease-modifying antirheumatic drugs, swollen joints are a better predictor of synovitis than tender joints, according to data published in Rheumatology Advances in Practice.